ESKD · patients with induction therapy in lupus nephritis
It is very uncertain whether mycophenolate mofetil (MMF) changes ESKD compared with IV cyclophosphamide (CPA) (very low certainty).
1 finding from 1 review
Complete renal remission · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) showed no clear difference in complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Partial renal remission · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Ovarian failure · patients with induction therapy in lupus nephritis
It is very uncertain whether mycophenolate mofetil (MMF) changes ovarian failure compared with IV cyclophosphamide (CPA) (very low certainty).
1 finding from 1 review
Major infection · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) showed no clear difference in major infection compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Alopecia · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) probably leads to lower alopecia compared with IV cyclophosphamide (CPA) (moderate certainty).
1 finding from 1 review
Diarrhoea · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) probably leads to higher diarrhoea compared with IV cyclophosphamide (CPA) (moderate certainty).
1 finding from 1 review
Death, all cause · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) showed no clear difference in death, all cause compared with azathioprine (AZA) (moderate certainty).
1 finding from 1 review
Graft loss censored for death · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower graft loss, censored for death compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Malignancy · patients with kidney transplant recipients
It is very uncertain whether mycophenolate mofetil (MMF) changes malignancy, any compared with azathioprine (AZA) (very low certainty).
1 finding from 1 review
Acute rejection, steroid resistant/antibody treated As reported in the articles · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower acute rejection, steroid resistant/antibody treated As reported in… compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Infection, CMV tissue invasive As reported in the articles · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to higher infection, CMV tissue invasive As reported in the articles compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Acute rejection, total Any treated acute rejection, including biopsy‐proven · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower acute rejection, total Any treated acute rejection, including… compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Chronic allograft nephropathy Biopsy required in 2 RCTs, one study with optional biopsy · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) may leads to lower chronic allograft nephropathy Biopsy required in 2 RCTs, one study… compared with azathioprine (AZA) (low certainty).
1 finding from 1 review
Cognition Semantic Fluency · people with a primary brain tumour
1 finding from 1 review
Cognition Lexical Fluency · people with a primary brain tumour
1 finding from 1 review
Cognitive subdomain: episodic memory measured at the end of · people with a primary brain tumour
1 finding from 1 review
Cognitive function · people with a primary brain tumour
1 finding from 1 review
Affectivity Norris Scale · people with a primary brain tumour
1 finding from 1 review
Apathy Marin Scale · people with a primary brain tumour
1 finding from 1 review